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Abstract
Background: This study aimed to find novel biomarkers for colorectal cancer.
Methods: Fluorescent mRNA differential display PCR (DD-PCR) was used to screen the genes
differentially expressed in colorectal cancer tissues and their adjacent tissues. The differentially
expressed genes were confirmed by real-time PCR and then their clinical relevance (such as
association with tumor location and lymph gland metastasis) was further investigated.
Results:  We identified by DD-PCR a novel RNA helicase, DHX32, which showed higher
expression in colorectal cancer tissues than their adjacent tissues, and this result was confirmed by
real time RT-PCR. In addition, we found that the level of DHX32 gene expression in colorectal
cancer was significantly associated with cancer location, lymph gland metastasis, cancer nodal
status, differentiation grade, and Dukes, stage.
Conclusion: DHX32 may play an important role in the development of colorectal cancer and
could serve as a novel biomarker for colorectal cancer after additional investigation.
Background
Colorectal cancer (CRC) is one of the most common
causes of cancer death throughout the world. Multistage
development of the disease has been associated with
remarkable genetic events, mainly at the level of onco-
genes and oncosuppressor genes, most notably the adeno-
matous polyposis coli gene (APC) [1], ras [2,3], and p53
[4]. Although great advances have been made during the
last few decades in understanding the molecular biology
of colorectal cancer [5], the prognosis of patients with this
neoplasm has not improved in parallel. The overall five-
year survival rate remains poor (40–45%) [6]. It can be
assumed that several genes involved in the pathogenesis
of colorectal cancer are still unknown. Therefore, further
elucidation of the molecular biology of colorectal cancer
may be useful to devise new methods for the diagnosis
and the treatment of the disease.
Several approaches have been taken to identify and com-
pare gene expression in normal and disease states [7-11].
The differential display technique was employed in this
study based on its ability to identify both up-regulated
genes (putative oncogenes) and down-regulated genes
(putative tumor/metastasis suppressor genes) simultane-
ously. Differential Display (DD) is a useful method to
compare patterns of gene expression in RNA samples of
different types or under different biological conditions
[8,9]. The technique produces partial cDNA fragments by
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a combination of reverse transcription (RT) and PCR of
randomly primed RNA. Changes in the expression level of
genes are identified after separation of the cDNA frag-
ments produced in an arbitrarily primed polymerase
chain reaction on a sequencing-type gel. When combined
with real-time quantitative PCR to eliminate false posi-
tives, DD becomes a powerful method for generating high
confidence hits in the screening of hundreds of poten-
tially differentially expressed transcripts. A number of
genes such as UCC1 [12], Reg [13], and PIGR [14] have
been detected by DD-PCR to be associated with colorectal
cancer.
In this study, we found that DHX32, a novel RNA helicase,
was significantly up-regulated in colorectal cancer com-
pared to its adjacent normal tissue using a combination of
DD-PCR and real-time PCR methods. Our results sug-
gested that the level of DHX32 gene expression in colorec-
tal cancer was significantly associated with cancer
location, lymph gland metastasis, cancer nodal status, dif-
ferentiation grade and Dukes' stage.
Methods
Subjects
34 pairs of specimens (tumor tissues and their adjacent
normal tissues) and 14 tumor tissues were obtained from
patients with colorectal cancer who underwent surgical
resection at the Xiamen Zhongshan Hospital, Xiamen
University in Xiamen during 2006 and 2007. The detail
clinical and pathological characteristics of these 48 cases
of samples were listed in a table 1. Adjacent normal tissues
were defined as tissues which have no sign of cancer by
visual inspection and which were located 3–5 cm sur-
rounding the boundary of the cancer tissues. All of the
patients gave informed consent prior to surgery. All speci-
mens were reevaluated by a pathologist in the hospital.
The specimens for assay were snap-frozen and stored in
liquid nitrogen until analysis.
RNA extraction and cDNA synthesis
Total RNA was prepared using Trizol reagent (Invitrogen,
California, USA) according to the manufacturer's instruc-
tions. RNA was treated with DNase? (Invitrogen, Califor-
nia, USA) in the presence of 50 μM T7(dT12)AP2,
T7(dT12)AP7 primer in 20 μl RT buffer (1×PCR buffer, 10
mM DTT, 0.25 mM dNTP), at 25°C for 5 minutes, fol-
lowed by 42°C for 10 minutes and 50°C for 60 minutes.
Reverse transcriptase was inactivated at 70°C for 15 min-
utes.
Differential display
Differential display was performed using Hieroglyph
mRNA Profile kit (Beckman, California, USA). Briefly,
PCR amplification was done using 1.5 μl of the cDNA,
primed with arbitrary P primer and anchored T primer.
Amplification at (95°C 2 minutes) 1 cycle, (94°C for 15
seconds, 50°C for 60 seconds, 72°C for 2 minutes) 4
cycles, (94°C for 15 seconds, 60°C for 30 seconds, 72°C
for 2 minutes) 25 cycles, followed by a final extension at
72°C for 7 minutes on a GeneAmp PCR system 9600 (Per-
kin-Elmer, Norwalk, USA). Following amplification of
randomly primed mRNAs by RT-PCR, the cDNA products
were heated at 94°C for 2 minutes and separated on a
denaturing 5.6% polyacrylamide gel using a Genomyx LR
DNA Sequencer (Beckman, California, USA). Bands exclu-
sively present in either of two samples were considered as
candidates of differentially expressed transcripts, which
were excised, eluted, re-amplified, and subcloned into the
pGEM-T easy vector (Promega, Madison, USA). The
sequence reactions were performed by Invitrogen Corp
(California, USA). Sequence homology to published data-
base was analyzed with the BLAST program at the internet
site of NCBI (National Center for Biotechnology Informa-
tion) http://www.ncbi.nlm.nih.gov/blast/blast.cgi.
Table 1: Patients characteristics (n = 48)
n (%)
Age (year)
<59 25(52.1)
≥ 59 23(47.9)
Gender
Male 22(45.8)
Female 26(54.2)
Tumor Location
Colon 10(20.8)
Rectum 38(79.2)
Polypi
+ 14(29.2)
- 34(70.8)
Lymph metastases
+ 27(56.3)
- 21(43.7)
Tumor Nodal
+ 20(41.7)
- 28(58.3)
Tumor Differentiation
Poor 9(18.8)
Median + WELL 39(81.2)
Dukes, Stage
A+B 21(43.8)
C+D 27(56.2)Journal of Experimental & Clinical Cancer Research 2009, 28:11 http://www.jeccr.com/content/28/1/11
Page 3 of 7
(page number not for citation purposes)
Real-time quantitative reverse transcription polymerase 
chain reaction
We measured DHX32 expression in 48 tumor samples by
real-time quantitative RT-PCR using TaqMan methodol-
ogy in an ABI PRISM 7500 Sequence Detection System.
The real-time RT-PCR allows, by means of fluorescence
emission, the identification of the cycling point when
PCR product is detectable. The Ct value inversely corre-
lates with the starting quantity of target mRNA. Measure-
ments were performed in duplicate and the controls were
included in which the reaction mixture contained no
cDNA. The amount of target mRNA after normalized to
the endogenous reference β-actin was calculated by the Ct
method as described by Liu W [15].
Primers and probes for β-actin and DHX32 mRNAs were
chosen using the Primer Express 2.0 software (Applied
Biosystems, Foster City, USA). The primers, placed in dif-
ferent exons, were designed to ensure that genomic DNA
would not be amplified. Primer and probe nucleotide
sequences for DHX32  (GenBank accession number
NM_018180) were: DHX32-Fw 5'-GTCTTTCCATCCAC-
TACCAGCAC-3', DHX32-Rev 5'-ATGATGACCCCAT-
AGCT ACCCAA-3', and TaqMan probe 5'-(FAM)
CGTGATATGCACACAGGTCCACAAG C (TAMRA)-3'.
Primers and probe for β-actin mRNA were: β-actin-Fw 5'-
TCACCCACACTGTGCCCATCTACGA-3',  β-actin-Rev 5'-
CAGCGGAACCGCTCATTGCCAATGG-3', and TaqMan
probe 5'-(FAM)ATGCCC-X(TAMRA)-CCCCCAT-
GCCATCCTGCGT-3'. Probes were purchased from Invit-
rogen Corp (Invitrogen, California, USA). The thermal
cycling conditions were: 5 minutes at 95°C, followed by
60 cycles of 30 seconds at 95°C and 1 minute at 60°C.
Statistic analysis
The Levene's test was performed to determine the homo-
geneity of variance for all the data, and then the paired
Chi-Square test or 2-related samples Wilcoxon nonpara-
metric test was performed to compare the positive rates
and the levels of DHX32 gene expression between tumor
tissue and its adjacent normal tissue in each patient,
respectively. The Mann-Whitney U test was used for com-
paring the gene expression of DHX32 between the differ-
ent groups according to various clinical and pathological
variables. All of the statistical analyses were performed
with SPSS 14.0 (Chicago, USA). A P value of less than 0.05
was considered to be statistically significant.
Results
Identification of a gene differentially expressed in the 
colorectal tumor and the adjacent normal tissue using DD-
PCR
The modified DD-PCR method was used to identify genes
uniquely and/or highly expressed in human CRC tissues
by comparing with those in adjacent normal tissues. One
cDNA band (size ranging between 700 bp and 800 bp)
was found to be highly expressed in colorectal cancer tis-
sues while barely expressed in matched adjacent normal
tissues. The identified band was recovered, re-amplified,
subcloned and sequenced. BLAST analysis of this nucle-
otide sequence revealed 99% homology to the gene
DHX32 in the GenBank database.
Confirmation of DHX32 differently expressed in colorectal 
tumors (CT) and their adjacent normal tissues (ANT) by 
real-time PCR
We compared both positive rate and gene expression level
in order to confirm the difference of DHX32 gene expres-
sion between colorectal tumors and their adjacent normal
tissues. We found that the positive rate of DHX32 gene
expression was significantly higher in the colorectal
tumors (76.5%) than that in the adjacent normal tissues
(26.4%) (Table 2). Consistent with the higher positive
rate of DHX32 gene expression in the colorectal tumors,
its gene expression level was also significantly higher than
that in the adjacent normal tissues (Figure 1). In addition,
the distribution of the patients with decreased, constant
or increased gene expression of DHX32 was also analyzed.
Whether it was decreased, constant or increased expres-
sion for each patient was arbitrarily classified according to
the gene expression ratios between the tumor tissue and
its adjacent normal tissue in each patient as described in
the literature [16]: decreased expression (<0.8), constant
expression (0.8~1.2), increased expression (>1.2). Tumor
tissues from 58.8% of the patients displayed increased
Comparison of DHX32 gene expression between colorectal  tumors (CT) and their adjacent normal tissues (ANT)  DHX32 gene expression in colorectal tumors was signifi- cantly higher than that in their adjacent normal tissues Figure 1
Comparison of DHX32 gene expression between 
colorectal tumors (CT) and their adjacent normal 
tissues (ANT) DHX32 gene expression in colorectal 
tumors was significantly higher than that in their 
adjacent normal tissues. Data were expressed with Box 
& Whiskers. ANT: Adjacent normal tissue; CT: Cancer tis-
sues. *: P < 0.05.Journal of Experimental & Clinical Cancer Research 2009, 28:11 http://www.jeccr.com/content/28/1/11
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gene expression of DHX32. Those from 29.4% of the
patients did not change and those from 11.8% of the
patients even showed decreased gene expression of
DHX32 (Table 3).
Relationships between DHX32 gene expression and 
clinically pathological parameters
In order to determine the relationships between DHX32
gene expression and the clinical-pathological parameters
(age, gender, tumor location, Polypi, lymph metastases,
nodal status, differentiation grade, and Dukes' stage), we
compared the positive rate and the levels of DHX32 gene
expression between the different groups according to var-
ious clinical and pathological variables. Although we did
not observe significant differences of the positive rate of
DHX32 gene expression between the groups according to
each parameter (data not shown), our results suggested
that the level of DHX32 gene expression in colorectal car-
cinoma was significantly associated with tumor location,
lymph gland metastasis, tumor nodal status, differentia-
tion grade and Dukes' stage (P < 0.05) (Figure 2). There
were no apparent differences of DHX32 gene expression
between the different groups classified by age, gender, and
Polypi.
Discussion
The study of the molecular biology of colorectal cancer
has progressed rapidly, but the survival of patients with
this neoplasm has improved rather modestly [17]. Conse-
quently, further studies of CRC-related genes would help
better understand the tumorigenesis of CRC and develop
new methods for population screening, follow-up of
treated patients, prognosis, and new therapies of the dis-
ease. In this study, we demonstrated that human DHX32,
a novel RNA helicase, was up-regulated in colorectal can-
cer compared to its adjacent normal tissues. Furthermore,
our results suggested that the level of DHX32 gene expres-
sion in colorectal carcinoma was significantly associated
with tumor location, lymph gland metastasis, tumor
nodal status, differentiation grade, and Dukes' stage.
DHX32 was originally identified as a novel RNA helicase
with unique structure in the helicase domain, but with
overall similarity to the DHX family of helicases [18].
RNA helicases are enzymes that utilize the energy derived
from nucleotide triphosphate (NTP) hydrolysis to modu-
late the structure of RNA molecules and thus potentially
influence all biochemical steps involving RNA which at
least include transcription, splicing, transport, translation,
decay, and ribosome biogenesis [19,20]. The involvement
of RNA molecules in these steps is influenced by their ten-
dency to form secondary structures and by their interac-
tion with other RNA molecules and proteins [21]. DHX32
is composed of 12 exons spanning a 60-kb region at
human chromosome 10q26 and encodes for a 743 amino
acid protein with a predicted molecular weight of 84.4
kDa. DHX32 has a widespread tissue distribution and also
has cross-species counterparts, such as 84 and 80% amino
acid identity with mouse and rat counterparts, respec-
tively. The high level of similarity between human and
murine DHX32 and the widespread expression of DHX32
message suggest that it is an evolutionally conserved and
functionally important gene.
With a few notable exceptions, the biochemical activities
and biological roles of RNA helicases, including DHX32,
are not very well characterized. In our study, we found
that DHX32 was overexpressed in colorectal cancer com-
pared with the adjacent normal tissues, suggesting that
abnormal expression of DHX32  is associated with the
development of colorectal cancer. The involvement of
DHX32 in other cancer development was previously dem-
onstrated by other groups. For example, the expression of
DHX32 was dysregulated in several lymphoid malignan-
cies [18,22]. DHX32 was reported as anti-sense to another
gene, BCCIP (BRCA2 and CDKN1A Interacting Protein),
and BCCIP was down-regulated in kidney tumors [23].
The overexpression of one of BCCIP isoforms can inhibit
tumor growth [24].
So far, several groups have attempted to reveal the under-
lying mechanisms by which DHX32 involves in cancer
development, but the exact biochemical activities and
biological functions of DHX32 are still elusive. DHX32
contains sequences which are highly conserved between a
subfamily of DEAH RNA helicases, including the yeast
pre-mRNA splicing factor Prp43 [25], and its mammalian
ortholog DHX15. The structural similarity of DHX32 to
RNA helicases involved in mRNA splicing suggests a role
Table 2: The positive rate of DHX32 gene expression in the 
colorectal tumors and adjacent normal tissues
Group DHX32 gene expression+ Positive rate
+-
Tumor tissue 26 8 76.5% *
Adjacent normal tissue 9 25 26.4%
*: P < 0.01
Table 3: DHX32 gene expression in the colorectal tumors and 
their adjacent normal tissues
Gene expression of DHX32 (CT/ANT, n = 34)
<0.8 0.8~1.2 >1.2
Patients 4 (11.8%) 10 (29.4%) 20 (58.8%)
1. CT (+) and ANT (-) treated as >1.2; 2. CT (-) and ANT (+) treated 
as <0.8; 3. CT (-) and ANT (-) treated as 1.Journal of Experimental & Clinical Cancer Research 2009, 28:11 http://www.jeccr.com/content/28/1/11
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in pre-mRNA splicing. It is possible that the dysregulation
of the normal function of RNA helicases can potentially
result in abnormal RNA processing with deleterious
effects on the expression/function of key proteins in nor-
mal cell cycles and contribute to cancer development and/
or progression. There are several examples of dyregulation
of RNA helicases in cancer [26], mostly in the forms of
overexpression including those of DDX5 [27] and DDX6
[28] which were reported to be overexpressed in colorectal
tumor.
The relationships between DHX32 gene expression and the clinical-pathological parameters (age, gender, tumor location,  Polypi, lymph metastases, nodal status, differentiation grade and Dukes, stage) Figure 2
The relationships between DHX32 gene expression and the clinical-pathological parameters (age, gender, 
tumor location, Polypi, lymph metastases, nodal status, differentiation grade and Dukes, stage) DHX32 gene 
expression in colorectal carcinoma was not significantly associated with age (A), gender (B) and Polypi (D), but associated 
with tumor location (C), lymph gland metastasis (E), tumor nodal Status (F), differentiation grade (G) and Dukes, stage (H). 
Data were expressed with Box & Whiskers. *: P < 0.05.Journal of Experimental & Clinical Cancer Research 2009, 28:11 http://www.jeccr.com/content/28/1/11
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Our results indicated that the differential expression of
DHX32 in colorectal carcinoma was significantly associ-
ated with tumor location, lymph gland metastasis, tumor
nodal status, differentiation grade, and Dukes' stage.
These results not only further confirmed the possible crit-
ical role of DHX32 in human colorectal development, but
also suggested that additional studies may help develop
DHX32 as a potential biomarker to judge the prognosis of
colorectal cancer patients: the patients with higher gene
expression of DHX32 may have worse prognosis.
In conclusion, to our knowledge, we are the first to report
the more frequent and significant overexpression of
human DHX32 in human CRC than that of the adjacent
normal tissue, indicating that overexpression of DHX32
may play a pivotal role in the multistage carcinogenesis of
human CRC. It still remains to be further investigated for
the functions of DHX32 during the progression of color-
ectal cancer. DHX32 may also serve as a bio-marker for
judging the levels of malignancy of colorectal cancer,
which may guide the development of anticancer therapy
regime after additional studies.
Conclusion
DHX32 may play an important role in the development of
colorectal cancer and additional studies may help use
DHX32 as a novel biomarker for colorectal cancer.
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